OSP News

FDA Grants New Indication for Liraglutide (Victoza)

Posted: 08/29/2017

Liraglutide’s new indication for cardiovascular protection includes reducing the risk of myocardial infarction, stroke, and cardiovascular death in adults with type 2 diabetes who have established cardiovascular disease. The approval was based on results from the LEADER trial where liraglutide reduced the risk for cardiovascular death, nonfatal myocardial infarction, and nonfatal stroke by 13% when compared to placebo.

Liraglutide is the second drug that was initially approved for glucose lowering in type 2 diabetes and has gained an indication for cardiovascular benefit. The new approval for liraglutide is broader than empagliflozin’s in that it includes prevention of cardiovascular events as well as death. 

 

We value your privacy. We use cookies and other technologies to keep the web site reliable and secure, tailor your experience, and measure web site performance, as described in our Privacy Policy.

x

OSP Technical Support